New drug combo IDB-011 tested for safety against rift valley fever
NCT ID NCT06925919
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing the safety of a new drug combination called IDB-011 in 40 healthy adults. The goal is to see if it is safe and how the body processes it, as a first step toward possibly preventing Rift Valley Fever, a viral disease spread by mosquitoes. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IDB-011 (a combination of two drugs: IDB-774 and IDB-898)
- What this could lead to
- If this early safety study goes well, it could pave the way for a preventive treatment against Rift Valley Fever, a serious viral disease.
- What could go wrong
- This is a very early Phase 1 trial with only 40 healthy people. It only tests safety and how the drug moves in the body, not whether it actually prevents disease. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIFT VALLEY FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences Clinical Los Angeles
Cypress, California, 90630, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.